Molnupiravir gets EUA from FDA; Pfizer also gets nod for use on 5-11-year-old kids

Share this information:

THE Food and Drug Administration (FDA) of the the Philippines gave the go-signal for emergency use of Molnupiravir, the anti-COVID-19 pill developed by Merck & Co. Inc.

Molnupiravir, to be called Molnarz as its brand name and is the world’s first oral antiviral medication for COVID-19, will be used primarily for treatment of adult patients with mild to moderate COVID-19 symptoms and who are at risk for developing severe symptoms, FDA Director-General Eric Domngo said in a public briefing.

The pill should be given as soon as possible after a patient had been diagnosed with COVID-19 and within five days after the onset of symptoms, he added.

The FDA earlier allowed the use of Molnupiravir in many hospitals in the country under a Compassionate Special Permit

The FDA also announced during the same briefing that Emergency Use Authorization (EUA) had been granted to Pfizer-BioNTech COVID-19 vaccine for children aged 5-11 years old and to be administered once it is available.

Domingo said the EUA was given “upon review of technical documents and evaluation of US FDA recommendations, and deemed that the data submitted is sufficient for EUA approval.”

He said that the benefits outweigh the risks DA chief Rolando Enrique Domingo told a public briefing the benefits outweighed the known and potential risks.”

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.